Louis Kuritzky, MD; Benjamin J. Epstein, PharmD, BCPS; and Frank Lavernia, MD Abstract: Good control of diabetes provides meaningful microvascular risk reduction; yet, patients with type 2 diabetes mellitus commonly languish at unsatisfactory levels of glycated hemoglobin (HbA1c) for protracted periods. A variety of factors contribute to this clinical inertia, as …

Frank Lavernia, MD Abstract: Objective This article describes a patient with type 2 diabetes mellitus achieving glycemic control after transitioning from premixed to basal-prandial insulin.

Daniel A. Nadeau, MD Abstract: The prevalence of type 2 diabetes mellitus has reached epidemic proportions. Current treatment options for patients with diabetes include lifestyle modifications (eg, diet and exercise) along with pharmacotherapy (eg, oral antidiabetic drugs [OADs], incretin-based therapies, and insulin). Despite the availability of effective and safe treatments, …

Rosiglitazone: FDA Keeps It and the Europeans Yank It! The European Medicines Agency has recommended that rosiglitazone (Avandia) and all medications containing the drug be taken off the market. The FDA says rosiglitazone can stay, but requiring a risk evaluation and mitigation strategy (REMS) program with additional measures to ensure …

iBGStar iPhone diabetes device Sanofi-Aventis launched its iBGStar hybrid medical device to monitor blood glucose levels that can also be plugged into an iPhone or an iPod touch. The iBGStar is a USB-sized blood glucose monitor that works as a standalone monitor, or it can be used with the new iBGStar …

Understanding Insulin Therapy This week’s Nipro Diagnostics TRUEinsight Guide focuses on understanding the goals of insulin therapy and the types of insulin on the market. It also teaches about insulin delivery options and the importance of blood glucose monitoring to determine if your diabetes management plan is effective in achieving …

EASD: Novel DPP-4 Drug Works in Renal Impairment: The novel diabetes drug linagliptin (proposed trade name Ondero) may find a niche in treating patients with kidney problems. In a phase III study of patients who couldn’t take metformin because of the drug’s GI side effects or renal impairment, linagliptin effectively …

EASD: Lixisenatide Shows Potential: Lixisenatide monotherapy significantly improves glycemic control with a pronounced postprandial effect in patients with Type 2 diabetes, and is safe and well tolerated, according to a phase 3 trial. Lixisenatide is a new potent and selective once-daily GLP-1 receptor agonist in development for the treatment of …

Adding exenatide to insulin glargine for patients who aren’t fully controlled with insulin glargine and/or other oral agents can help to improve their blood glucose….

Early treatment of screen-detected Type 2 diabetes works regardless of how intensively glucose, lipids, and blood pressure are managed, experts concluded on the basis of a large randomized trial presented….